glp-1 drugs insurance coverage of Obesity Therapies in State-Regulated Markets MCT2D | 2023 Updates to

Designing hydrogels for controlled drug delivery

doi: 10.3390/ijms19010026, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 96.Qi L, Gao R, Chen Z, Lin D, Liu Z, Wang L, et al

The most common risks of oral GLP-1s like Rybelsus, Wegovy pill, and Foundayo include : Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All three GLP-1s also carry a black box warning for thyroid tumors based on animal studies

Furthermore, a RCT (NCT03357380) is currently comparing the change in early stages of scar tissue as well as fat deposition in the liver, as detected by magnetic resonance imaging scans, in patients treated with semaglutide or placebo for 72 weeks